Key Highlights

● SpyGlass Pharma reported 12-month Phase 1/2 results showing a 34% mean reduction in intraocular pressure from its BIM-IOL glaucoma lens system, with $251.0 million in cash and runway guided through 2028.

● MapLight Therapeutics said its Phase 2 ZEPHYR trial met its primary endpoint on July 27, 2026, with betovumeline producing a 4.5-point mean reduction in PANSS total score versus placebo in schizophrenia.

● The RNA ticker changed hands after Novartis completed its Acquisition of Avidity Biosciences in early 2026, passing to spinout Atrium Therapeutics, which launched with approximately $270 million in cash for rare cardiomyopathy programs.

● The MMED ticker now belongs to MiniMed Group, the diabetes-device Business Medtronic listed on Nasdaq on March 6, 2026, after the psychedelics developer MindMed rebranded to Definium Therapeutics and moved to a different symbol.

A newly minted glaucoma player, a muscarinic-agonist story in schizophrenia, an oncology debutant, an RNA-cardiology spinout born from a Novartis deal, and Medtronic's freshly listed diabetes business show how much the healthcare corner of the Nasdaq Composite has reshuffled in a single year, and why the tickers no longer mean what many assume.

Five Tickers, Five Different Stories

If these five symbols sound like familiar names, most would surprise you. SGP is SpyGlass Pharma, a 2026 ophthalmology IPO. MPLT is MapLight Therapeutics, a central-nervous-system biotech. BLSM is BlossomHill Therapeutics, an oncology debutant. RNA no longer belongs to Avidity Biosciences; Novartis bought Avidity and the symbol passed to a spinout, Atrium Therapeutics. And MMED is not MindMed, the psychedelics developer; it is MiniMed Group, Medtronic's diabetes business, which took the symbol after MindMed rebranded and moved on. What links them is timing: all five arrived or transformed in 2026, and each sits at a different point on the Risk Curve within the same index.

A 2026 Backdrop of Open Windows and Selective Buyers

The healthcare slice of the Nasdaq Composite entered late 2026 in a livelier mood than it had seen in years. By mid-year, 13 venture-backed biotechs had completed US IPOs, and 11 of them raised at least $250 million, with Parabilis Medicines and Kailera Therapeutics each setting records that topped Moderna's long-standing High-Water Mark for a biotech offering. Most 2026 debutants were trading at or above their listing prices by mid-year.

Nasdaq's Dan Angius summarized the tone bluntly: the window's open. But the same coverage stressed a crucial caveat: this is a disciplined market. Nearly every company that listed had an asset in Phase 2 or later, a sharp break from the 2020 to 2021 boom when unproven platforms went public and later cratered.

That discipline is the throughline for the names below. Clinical-stage story stocks now need real data, real runway, and, increasingly, a differentiated mechanism. The M&A wave recycling Capital back into the sector, Novartis's Avidity purchase among the largest, is part of why the window stays propped open.

SpyGlass Pharma (NASDAQ:SGP): Betting the Lens Itself Becomes the Drug

SpyGlass Pharma is trying to solve glaucoma's oldest problem, patients forgetting their daily drops, by turning the intraocular lens implanted during routine cataract surgery into a sustained drug depot. Its lead program, the BIM-IOL system, pairs a standard lens with bimatoprost pads designed to lower intraocular pressure for roughly three years.

The data supporting the pitch look encouraging so far. In March 2026 the company reported positive 12-month Phase 1/2 results in which the 78-microgram dose produced a 34% mean reduction in intraocular pressure, with 98% of evaluable patients free from all topical pressure-lowering medications. Two Phase 3 registrational trials, SGP-005 and SGP-006, are underway, with first surgeries completed and enrollment expected to finish in 2027. A second candidate, BIM-DRS, was slated for a first-in-human study in the second half of 2026.

SpyGlass Pharma reported a Q1 2026 net loss of $13.8 million, versus $8.8 million a year earlier, and $251.0 million in cash and investments as of March 31, 2026, with runway guided through 2028 after its February 2026 IPO raised roughly $172.5 million. Phase 3 outcomes and any surgeon-adoption curve remain unproven and years away.

MapLight Therapeutics (NASDAQ:MPLT): A Muscarinic Story Meets a Skeptical Tape

MapLight Therapeutics is a neuropsychiatry company chasing one of the most closely watched targets in psychiatry, the muscarinic pathway that reached the market through Bristol Myers Squibb's Cobenfy. Its lead candidate, ML-007C-MA (betovumeline), is an oral, extended-release M1/M4 muscarinic agonist co-formulated with the peripherally acting anticholinergic fesoterodine to blunt side effects. The company listed in 2026 in an IPO that raised roughly $296 million, alongside a separate $150 million private placement.

On July 27, 2026, MapLight Therapeutics said its Phase 2 ZEPHYR trial in schizophrenia met its primary endpoint. The 210/3 mg twice-daily dose delivered a 4.5-point mean reduction in PANSS total score versus placebo (p=0.015), an effect size of 0.37, with supportive readouts on cognition (effect size 0.51, p=0.041) and clinical global impression (0.48, p=0.002). The company said it plans an end-of-Phase 2 FDA meeting and has already begun planning a confirmatory trial. A separate Phase 2, IRIS, tested ML-004 in autism spectrum disorder.

Meeting the endpoint and convincing the market are not the same thing. Some market commentators argued the effect size looked modest against established muscarinic benchmarks. The registrational path and competitive positioning against Cobenfy will not be settled until later trials read out.

BlossomHill Therapeutics (NASDAQ:BLSM): An Oversubscribed Bet on Beating Resistance

BlossomHill Therapeutics is the clean example of 2026's disciplined-but-open IPO window. The clinical-stage oncology company priced an upsized offering of 9,375,000 shares at $16.00 for $150 million in gross proceeds, and began trading on the Nasdaq Global Select Market on August 7, 2026. Trade press described the debut, alongside Latigo's, as oversubscribed.

The scientific hook is BH-30643, described by the company as a non-covalent, macrocyclic, brain-active, mutant-selective OMNI-EGFR inhibitor aimed at EGFR-mutant non-small cell lung cancer, including the stubborn C797S resistance mutation that limits current standards of care. Coverage framed it as a potential challenger to AstraZeneca's Tagrisso. Behind it sit BH-30236 for relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndrome, plus a preclinical KRAS program, BH-501284.

EGFR lung cancer is one of oncology's most crowded fields, so brain penetration and activity against resistance mutations are the differentiators BlossomHill Therapeutics has to prove. As an early clinical-stage name, its value hinges almost entirely on data that has not yet matured; the IPO buys time, not certainty.

Atrium Therapeutics (NASDAQ:RNA): The Symbol Changed Hands

Here the ticker itself tells the story. This symbol long belonged to Avidity Biosciences, a mid-cap innovator in antibody-oligonucleotide conjugates. Novartis agreed to acquire Avidity and completed the deal in early 2026; Avidity traded under the temporary symbol RNAM from February 26 and was suspended from Nasdaq around March 2, 2026. As part of the transaction, Avidity's earlier-stage cardiology Assets were spun out into a new independent public company, Atrium Therapeutics, which took over the symbol and began trading on the Nasdaq Global Select Market on February 27, 2026.

Atrium Therapeutics launched with approximately $270 million in cash to pursue RNA medicines for rare genetic cardiomyopathies, using a delivery platform the company says combines antibody-like tissue selectivity with oligonucleotide precision to route siRNA to cardiac tissue. Its disclosed programs are ATR 1072 for PRKAG2 syndrome, with an IND filing expected in the second half of 2026, and ATR 1086 for PLN cardiomyopathy, targeted for 2027. Kathleen Gallagher is CEO; former Avidity chief Sarah Boyce chairs the board.

Investors mapping this ticker to Avidity's late-stage neuromuscular pipeline are now holding a far earlier, preclinical-stage cardiology story, one whose platform is still unproven in the clinic.

MiniMed Group (NASDAQ:MMED): The Health-Technology Name Hiding in a Biotech List

This ticker is the reason this basket spans health technology, not just biotech. The symbol now belongs to MiniMed Group, the diabetes business Medtronic carved out and listed publicly. MiniMed Group launched its IPO roadshow on February 24, 2026, and began trading on the Nasdaq Global Select Market on March 6, 2026. The company develops integrated insulin delivery systems, continuous glucose monitors, dosing algorithms and connected apps, and says it serves people with diabetes across 80 countries.

Crucially, this is not MindMed. The psychedelics developer many associate with that symbol rebranded to Definium Therapeutics and changed its Nasdaq ticker from MNMD to DFTX in January 2026. Anyone searching for a clinical-stage LSD program under the old symbol in 2026 is instead buying a commercial-scale medical-device business.

That makes MiniMed Group a fundamentally different risk profile from its neighbors here, an established, revenue-generating device Franchise rather than a data-dependent biotech. As a newly independent public company, its standalone margins, competitive standing against Dexcom and Abbott, and disclosure cadence still have to establish a track record; final IPO pricing details were not disclosed in the materials reviewed.

What Investors Should Watch

The near-term catalysts cluster around data and filings. For SpyGlass Pharma, watch Phase 3 enrollment progress and the BIM-DRS first-in-human start. For MapLight Therapeutics, the end-of-Phase 2 FDA interaction and confirmatory-trial design will decide whether ZEPHYR's modest effect size can support a registration path. BlossomHill Therapeutics's value turns on BH-30643 clinical readouts in EGFR-mutant lung cancer. Atrium Therapeutics's credibility rests on hitting its ATR 1072 IND timeline. And MiniMed Group's first reporting periods as a standalone company will reveal how the diabetes franchise performs outside Medtronic's umbrella.

Across the micro-cap and clinical-stage names, financing discipline matters as much as science. Cash runway, dilution risk and, for the smallest names, Nasdaq listing compliance are the guardrails to monitor. None of the five verified here currently shows a going-concern or delisting flag in the sources reviewed, but that can change quickly for pre-revenue biotech.

When the Ticker Outlives the Company Behind It

All five tickers are live Nasdaq listings as of mid-September 2026, but four of the five carry identities that differ from common assumptions: SGP, MPLT and BLSM are 2026 IPOs, and RNA and MMED changed hands entirely. Together they sketch the 2026 healthcare Nasdaq in miniature, an open but selective IPO window, an active M&A engine reshuffling symbols, and a spectrum running from commercial MedTech at MiniMed Group to preclinical RNA cardiology at Atrium Therapeutics. The science is early for most, and valuations are catalyst-dependent, which makes verifying the ticker before trading it the first step, not an afterthought.